GOSS Stock Analysis: Buy, Sell, or Hold?
GOSS - Gossamer Bio, Inc. Common Stock
$2.48
0.20 (8.77%)
▲
5d:
-6.77%
30d:
-20.0%
90d:
+2.48%
HOLD
LOW Confidence
Last Updated: February 2, 2026
Earnings: Mar 12, 2026
Smart Money Accumulation
GOSS is down 3.6% this week, but smart money is accumulating calls. Top strike: $3 2026-03-20 with 36,285 OI. Call ratio: 100% View Scanner →
Strength: 6.8/10
Get Alerted When GOSS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called GOSS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GOSS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GOSS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GOSS is currently trading at $2.48, which is considered slightly low relative to its 30-day fair value range of $2.42 to $2.93.
Technical Outlook: Technically, GOSS is in a strong uptrend. Immediate support is located at $2.27, while resistance sits at $3.00. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: GOSS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.43 (+280.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GOSS is in a strong uptrend. Immediate support is located at $2.27, while resistance sits at $3.00. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: GOSS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.43 (+280.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$2.42 -
$2.93
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.8%)
- BULLISH: Trading 280.2% below Wall St target ($9.43)
- CAUTION: Recommendation downgraded due to -6.8% 5-day decline
Fair Price Analysis
30-Day Fair Range
$2.42 -
$2.93
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.27
Resistance Level
$3.00
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-4.29
Wall Street Target
$9.43
(+280.2%)
Revenue Growth (YoY)
40.2%
Last updated: February 02, 2026 9:10 PM ET
Data refreshes hourly during market hours. Next update: 10:10 PM
Data refreshes hourly during market hours. Next update: 10:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GOSS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 57 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$71 | 60 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$42 | 56 HOLD |
